{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/0xa5ma0qxwr9",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1001/jamaneurol.2024.0991"
  ],
  "dcterms:references": [
    "# Mechanistic Hypothesis Connecting DOPAL's Anti-Oligomerization Effect with Neprilysin-Mediated Amyloid-β Degradation\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive aldehyde metabolite of dopamine, has been demonstrated to decrease Aβ oligomerization in human neuroblastoma cells, thereby reducing the cytotoxic effects of aggregated Aβ species. Neprilysin (NEP) is a zinc-dependent metalloendopeptidase that serves as a primary Aβ-degrading enzyme, preferentially cleaving monomeric Aβ peptides. As shown in Abstract 1, L-DOPA administration in 5xFAD mice significantly decreased Aβ plaque burden through upregulation of neprilysin and ADAM17, suggesting a mechanistic link between dopamine metabolism and Aβ clearance pathways that extends beyond simply modulating substrate availability.\n\n## 2. Knowledge Gap\nWhile previous hypotheses have suggested that DOPAL may maintain Aβ in a monomeric state suitable for neprilysin degradation, the potential direct signaling role of DOPAL in regulating neprilysin expression remains unexplored. Specifically, how DOPAL might function as both an anti-oligomerization agent and a signaling molecule that upregulates Aβ-degrading enzymes represents a critical knowledge gap in understanding the interplay between dopamine metabolism and amyloid processing.\n\n## 3. Central Hypothesis\nDOPAL functions as a bifunctional neuroprotective agent that both prevents Aβ oligomerization and simultaneously triggers redox-sensitive transcriptional upregulation of neprilysin, creating a coordinated cellular response that enhances Aβ clearance.\n\n## 4. Proposed Mechanism\n1. DOPAL, generated through MAO-B-mediated dopamine metabolism, covalently modifies specific lysine residues on Aβ peptides through Schiff base formation, inhibiting the conformational changes required for β-sheet formation and subsequent oligomerization.\n\n2. Concurrently, a portion of DOPAL acts as an electrophilic signaling molecule that activates the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway by modifying Keap1 (Kelch-like ECH-associated protein 1), allowing Nrf2 translocation to the nucleus.\n\n3. Nuclear Nrf2 binds to antioxidant response elements (AREs) in the promoter region of the neprilysin gene, upregulating its transcription as part of a coordinated cellular response to oxidative stress.\n\n4. The resulting increase in neprilysin expression enhances proteolytic capacity specifically for the monomeric Aβ maintained by DOPAL's anti-oligomerization effect.\n\n5. This dual-action mechanism creates a self-reinforcing neuroprotective loop where increased DOPAL levels both prevent Aβ toxicity through anti-oligomerization and accelerate Aβ clearance through neprilysin upregulation.\n\n## 5. Testable Predictions\n1. In neuronal cell cultures, application of physiologically relevant DOPAL concentrations should increase nuclear Nrf2 localization, ARE-dependent gene transcription, and specifically neprilysin mRNA and protein levels, effects that would be abolished by Nrf2 siRNA knockdown.\n\n2. DOPAL-treated cells should show both decreased Aβ oligomerization and increased neprilysin expression in a dose-dependent manner, with the neprilysin upregulation being blocked by Nrf2 pathway inhibitors but not affecting DOPAL's direct anti-oligomerization properties.\n\n3. In Nrf2 knockout mice crossed with AD models, L-DOPA administration should still show DOPAL-mediated inhibition of Aβ oligomerization but fail to upregulate neprilysin expression, resulting in less protection against Aβ pathology compared to Nrf2-intact controls.\n\n## 6. Potential Experimental Approaches\n1. **Cell-based redox signaling analysis**: Develop a reporter system in SH-SY5Y neuroblastoma cells using neprilysin promoter-driven luciferase constructs with wild-type or mutated ARE sites. Treat with varying concentrations of DOPAL and measure luciferase activity, neprilysin expression, and Aβ oligomerization simultaneously. Use chromatin immunoprecipitation to confirm Nrf2 binding to the neprilysin promoter following DOPAL treatment. Validate with Nrf2 knockdown or chemical inhibition.\n\n2. **In vivo pathway validation**: Administer L-DOPA to wild-type, 5xFAD, and 5xFAD/Nrf2 knockout mice, then analyze brain tissue for: (a) DOPAL levels via HPLC, (b) Aβ oligomerization states via native PAGE and immunoblotting, (c) neprilysin activity and expression, and (d) nuclear localization of Nrf2 in neurons surrounding Aβ plaques via immunohistochemistry. This approach would distinguish between DOPAL's direct anti-oligomerization effects and its Nrf2-dependent signaling functions in neprilysin regulation.\n\nThis hypothesis provides a novel mechanistic framework linking dopamine metabolism to Aβ processing through DOPAL's dual roles as both a direct anti-oligomerization agent and a redox-active signaling molecule that upregulates degradation pathways. It explains how a dopamine metabolite could simultaneously affect both Aβ aggregation state and clearance capacity, creating a coordinated neuroprotective response that might be therapeutically exploitable in Alzheimer's disease."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "Alzheimer disease"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "The study shows that neprilysin acts as an Aβ-degrading enzyme, particularly affecting monomeric Aβ"
  ],
  "dcterms:abstract": [
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "This randomized clinical trial investigates the effects of solanezumab and gantenerumab on downstream biomarkers in individuals with dominantly inherited Alzheimer disease."
  ]
}